9:00 am Virtual Coffee & Networking

9:25 am Chair’s Opening Remarks

Analyzing Tumor Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

9:30 am Protease Dependent COBRA™ Activity Regresses Established Tumors in Mice

  • Chad May Senior Vice President - Research & Development, Maverick Therapeutics


  • Solid tumor directed T cell engagers are limited by target expression on healthy tissues
  • COBRA platform is engineered to restrict T cell engagement to within the tumor microenvironment
  • COBRA design allows for the pursuit of more broadly expressed and validated targets

10:00 am Use of Quantitative Systems Pharmacology (QSP) Modeling to Drive Decision Making of T Cell Engager mAbs from Target Identification to Phase 1

  • Alison Betts Sr. Director of Scientific Collaborations and Fellow of Modeling & Simulation, Applied Biomath


  • Target feasibility and selection
  • Optimising drug format and Kds – impact on therapeutic window between low and high expressing cells
  • Translation from in vitro to in vivo data to the clinic
  • Predicting clinical starting and efficacious doses

10:30 am Morning Refreshments

11:00 am ProTriTAC: A New Protease-Activated T Cell Engager Platform to Target Broadly Expressed Tumor Antigens

  • Jack Lin Director of New Technologies , Harpoon Therapeutics


  • ProTriTAC is a T cell engager prodrug with tumor-restricted activity for improved safety
  • Half-life extension is coupled to functional masking for added protection
  • Expansion of therapeutic index was demonstrated with rodent and non-human primate models

Optimizing Next Generation Drug Discovery through Advances in Technology

11:30 am Landscape Review of CD3 Bispecifics

  • Raj Kumar Account Director - Beacon Bispecific, Beacon Targeted Therapies


  • Landscape overview of clinical CD3 bispecifics
  • Targets in combination with CD3
  • Assessment of CD3 bispecific preclinical space

12:00 pm Improving CD3 Bi-Specific Therapeutic Responses through Combination Regimens & Molecular Design

  • Paul Moore VP, Cell Biology and Immunology , MacroGenics


  • Enhancing CD3 bispecific molecule activity through combination with checkpoint inhibition or co-stimulation
  • Segregating cytolytic activity from cytokine response through molecular design
  • Maximizing CD3 bispecific exposure and durable pharmacodynamic activity with enhanced safety in non-human primates

12:30 pm Networking Lunch

1:30 pm A Novel Class of Antibodies to Enhance CD3 Bispecific Activity in Solid Tumors


  • Efficacy of CD3 bispecifics in solid tumors- and limitations
  • Modeling combinations of novel co-stimulatory bispecifics and CD3 bispecifics

Analyzing the Biology of T cells, NK cells & the Tumor Microenvironment to Improve Cell Engager Therapies

2:00 pm Comparing the Biology of Conditional Agonists Targeting CD3, the g9d2 TCR and NK Activation Receptors


  • The biology of activating ab T cells, g9d2 T cells and NK cells
  • Advantages and disadvantages to conditional agonists targeting each cell type
  • Challenges and opportunities associated with targeting activation receptors expressed on multiple effector cell types

2:30 pm Bispecific γδ-T cell Engagers for Cancer Immunotherapy


  • Background on Vγ9Vδ2 T cells and their role in antitumor immunity
  • Generation and preclinical evaluation of bispecific Vγ9Vδ2 T cell engagers as novel tools for cancer immunotherapy

3:00 pm Online Networking Break

3:30 pm Opening up the Tumor Microenvironment to Enable T cell Directed Therapies & More


• The key resistance mechanism for T cell directed therapies are inhibitory myeloid
populations of cells in the tumor microenvironment
• By changing the way tumor associated macrophages and other myeloid cells
function, macrophage checkpoint modulators initiate and support comprehensive
anti-tumor immune response as single agent therapy in preclinical testing
• From biological principals and experimental data, these types of therapies will
likely become great combinations with T cell targeting

Comparing Cell Engagers with CAR Therapeutics and Bispecifics

4:00 pm Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3Bispecifics and CAR T Cells


  • Two competing platforms exist for redirecting T cells to recognize and kill tumors: Bispecific antibodies and chimeric antigen receptor (CAR) T cells
  • We have developed preclinical in vitro and in vivo models to mechanistically compare these two technologies and will discuss our findings as well as the clinical implications

4:30 pm Design Strategies and Insights on the Activity of Cell Engagers with CAR Therapeutics and Bispecifics


  • Molecular design strategies for multi-targeting bispecific antibodies and CAR-T to overcome immune surveillance, heterogeneity and antigen escape in solid tumors
  • Approaches for de-risking scFv binder modules to minimize Immune-related adverse events
  • Compare and contrast activity of anti-tumor targeting by bispecific antibodies versus CAR-T

5:00 pm Chair’s Closing Remarks & End of Virtual Conference